Rectal cancer surveillance · Endoscopic AI
Detect what remains. Recognize what returns.
PrecisionRect AI® is an AI tool for the detection of residual or recurrent rectal cancer on endoscopic imaging following total neoadjuvant therapy.
01 · Intended use
AI assistance for rectal surveillance after treatment.
PrecisionRect AI® detects residual disease or local regrowth in previously acquired endoscopic images following total neoadjuvant therapy.
The technology supports precision biopsy targeting through bounding boxes and generates standardized AI‑driven diagnostic reports.
The clinical challenge
Mucosal change after treatment can complicate surveillance.
Scarring, friability and vascular change after neoadjuvant therapy may make residual disease or local regrowth difficult to identify endoscopically.
“The goal is to distinguish expected treatment response from findings that require closer assessment.”
How it works
From surveillance image to focused clinical review.
PrecisionRect AI® supports post-treatment image review while keeping diagnosis and management decisions with the clinical team.
Surveillance image import
Previously acquired endoscopic images following total neoadjuvant therapy enter the review workflow.
Image preparation
Surveillance frames are prepared for consistent post‑procedural AI analysis.
Mucosal assessment
The model evaluates endoscopic patterns in the treated rectal site.
Disease detection
Residual disease or local regrowth is localized for clinical review and biopsy targeting.
Structured report
AI‑driven findings are organized into a standardized diagnostic report.
AI capabilities
Designed for endoscopic surveillance after neoadjuvant therapy.
Diagnostic accuracy presented for PrecisionRect AI®
Post‑treatment image analysis
Analyzes endoscopic images acquired following total neoadjuvant therapy.
Residual disease detection
Supports detection of endoscopic patterns associated with persistent rectal cancer.
Regrowth surveillance
Assists the identification of local regrowth during follow‑up imaging.
Precision biopsy guidance
Localizes relevant regions with bounding boxes to support targeted tissue sampling.
Standardized AI reporting
Generates consistent AI‑driven output for clinician validation.
Scientific validation
AI support for surveillance after treatment.
Use of artificial intelligence in analysis of endoscopic images to detect residual disease or regrowth in rectal patients with complete clinical response to neoadjuvant chemoradiotherapy
Techniques in Coloproctology · 2026 · 1,795 annotated frames
Read publication ↗Clinical benefits
Earlier detection. More focused surveillance.
Earlier and more accurate detection of rectal cancer lesions
↗More focused surveillance following total neoadjuvant therapy
↗Precision biopsy targeting with bounding‑box guidance
↗Post‑procedural analysis of previously acquired endoscopic images
↗Fewer unnecessary procedures and greater workflow efficiency
↗PrecisionRect AI®
Focus every review on the findings that matter most.
Talk to our team ↗This technology is part of DigestAID's research and development pipeline. Availability and regulatory status may vary by market.